yl202
mAbexperimentalADC
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 20, 2022 (NCT05653752)
Timeline
Indications
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3BINDING AGENT
ERBB3 binding agent
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07202364 | Phase 2 | Oct 15, 2025 | Suzhou Medilink Therapeutics Ltd. |
| NCT07111520 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2025 | Biontech, Suzhou Medilink Therapeutics Ltd. |
| NCT07169994 | Phase 1/Phase 2 (Phase 2) | Sep 2, 2025 | Suzhou Medilink Therapeutics Ltd. |
| NCT07070232 | Phase 1/Phase 2 (Phase 2) | Aug 12, 2025 | Biontech |
| NCT06439771 | Phase 2 | Apr 23, 2024 | Suzhou Medilink Therapeutics Ltd. |
| NCT06107686 | Phase 2 | Dec 31, 2023 | Suzhou Medilink Therapeutics Ltd. |
| NCT05653752 | Phase 1 | Dec 20, 2022 | Suzhou Medilink Therapeutics Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Medilink Therapeutics Ltd. | For profit | 6 | 5 | 2 | 2022 |
| Biontech | For profit | 2 | 2 | 1 | 2025 |
2 organizations
Page 1 / 1